SCOPUS 정보 검색 플랫폼

Revista Brasileira de Reumatologia

Volumn 50, Issue 3, 2010, Pages 223-224

Are we prepared to prescribe biosimilars?

(1) Azevedo, Valderilio Feijó a

a FEDERAL UNIVERSITY OF PARANÁ (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG; RECOMBINANT ERYTHROPOIETIN; BIOLOGICAL PRODUCT;

ANEMIA; BIOEQUIVALENCE; BIOLOGICAL ACTIVITY; BIOTECHNOLOGICAL PROCEDURES; DRUG EFFICACY; DRUG MANUFACTURE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EDITORIAL; FERMENTATION; HEALTH CARE COST; HEALTH CARE PERSONNEL; HUMAN; IMMUNOGENICITY; MEDICOLEGAL ASPECT; MOLECULAR WEIGHT; PRESCRIPTION; PUBLIC HEALTH PROBLEM; PURE RED CELL ANEMIA; PURIFICATION; STRUCTURE ANALYSIS;

BIOLOGICAL PRODUCTS; HUMANS;

EID: 77954700058 PISSN: 04825004 EISSN: None Source Type: Journal
DOI: None Document Type: Editorial

Times cited : (7)

References (13)

1
- 68349145179
- Biosimilars and follow-on biologics
- Fuhr JP. Biosimilars and follow-on biologics. Expert Rev Pharmacoecon Outcomes. Res 2009; 9(2):149-50.
- (2009) Expert Rev Pharmacoecon Outcomes. Res , vol.9 , Issue.2 , pp. 149-50
- Fuhr, J.P.¹

2
- 34248176896
- Biosimilars: Recent developments
- Covic A, Kuhlmann MK. Biosimilars: recent developments. Int Urol Nephrol. 2007; 39(1):261-6.
- (2007) Int Urol Nephrol , vol.39 , Issue.1 , pp. 261-266
- Covic, A.¹ Kuhlmann, M.K.²

3
- 77949469515
- Are biosimilars really generics?
- Misra A. Are biosimilars really generics? Expert Opin Biol Ther 2010; 10(4):489-94.
- (2010) Expert Opin Biol Ther , vol.10 , Issue.4 , pp. 489-94
- Misra, A.¹

4
- 67449138587
- Biosimilars: Science, status, and strategic perspective
- Kresse GB. Biosimilars: science, status, and strategic perspective. Eur J Pharm Biopharm 2009; 72(3):479-86.
- (2009) Eur J Pharm Biopharm , vol.72 , Issue.3 , pp. 479-86
- Kresse, G.B.¹

5
- 75749134951
- Assessing the safety and comparative effectiveness of follow-on biologics (biosimilars) in the United States
- Hennessy S, Leonard CE, Platt R. Assessing the safety and comparative effectiveness of follow-on biologics (biosimilars) in the United States. Clin Pharmacol Ther 2010; 87(2):157-9.
- (2010) Clin Pharmacol Ther , vol.87 , Issue.2 , pp. 157-159
- Hennessy, S.¹ Leonard, C.E.² Platt, R.³

6
- 75649122517
- Biosimilar medicines: New challenges for a new class of medicine
- Fox A. Biosimilar medicines: new challenges for a new class of medicine. J Biopharm Stat 2010; 20(1):3-9.
- (2010) J Biopharm Stat , vol.20 , Issue.1 , pp. 3-9
- Fox, A.¹

7
- 70449348153
- Follow-on protein products: Scientific issues, developments and challenges
- Rathore AS. Follow-on protein products: scientific issues, developments and challenges. Trends Biotechnol 2009; 27(12):698-705.
- (2009) Trends Biotechnol , vol.27 , Issue.12 , pp. 698-705
- Rathore, A.S.¹

8
- 48949117123
- Pharmacy and pharmacology of biosimilars
- Krämer I. Pharmacy and pharmacology of biosimilars. J Endocrinol Invest 2008; 31(5):479-88.
- (2008) J Endocrinol Invest , vol.31 , Issue.5 , pp. 479-88
- Krämer, I.¹

9
- 45949108207
- WHO Informal Consultation Group. WHO informal consultation on regulatory evaluation of therapeutic biological medicinal products held at WHO Headquarters
- Geneva, 19-20 April 2007
- Joung J, Robertson JS, Griffiths E, Knezevic I; WHO Informal Consultation Group. WHO informal consultation on regulatory evaluation of therapeutic biological medicinal products held at WHO Headquarters, Geneva, 19-20 April 2007. Biologicals 2008; 36(4):269-76.
- (2008) Biologicals , vol.36 , Issue.4 , pp. 269-76
- Joung, J.¹ Robertson, J.S.² Griffiths, E.³ Knezevic, I.⁴

10
- 75149181512
- Health economics of market access for biopharmaceuticals and biosimilars
- Simoens S. Health economics of market access for biopharmaceuticals and biosimilars. J Med Econ 2009; 12(3):211-8.
- (2009) J Med Econ , vol.12 , Issue.3 , pp. 211-218
- Simoens, S.¹

11
- 67549097000
- Regulatory aspects of biosimilars in Europe
- Zuñiga L, Calvo B. Regulatory aspects of biosimilars in Europe. Trends Biotechnol 2009; 27(7):385-7.
- (2009) Trends Biotechnol , vol.27 , Issue.7 , pp. 385-387
- Zuñiga, L.¹ Calvo, B.²

12
- 70449440279
- WHO guidelines presage US biosimilars legislation?
- Hodgson J. WHO guidelines presage US biosimilars legislation? Nat Biotechnol 2009; 27(11):963-5.
- (2009) Nat Biotechnol , vol.27 , Issue.11 , pp. 963-965
- Hodgson, J.¹

13
- 69449095403
- Biosimilar therapeutics-what do we need to consider?
- Schellekens H. Biosimilar therapeutics-what do we need to consider? NDT Plus 2009; 2(Suppl.1):i27-i36.
- (2009) NDT Plus , vol.2 , Issue.SUPPL. 1
- Schellekens, H.¹

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.